This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
Frontiers of Medicine Open Access 24 July 2018
-
Targeting Gas6/TAM in cancer cells and tumor microenvironment
Molecular Cancer Open Access 31 January 2018
-
Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy
Scientific Reports Open Access 06 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. First Axl inhibitor enters clinical trials. Nat Biotechnol 31, 775–776 (2013). https://doi.org/10.1038/nbt0913-775a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0913-775a
This article is cited by
-
The great escape: tumour cell plasticity in resistance to targeted therapy
Nature Reviews Drug Discovery (2020)
-
Targeting Gas6/TAM in cancer cells and tumor microenvironment
Molecular Cancer (2018)
-
Dual gene activation and knockout screen reveals directional dependencies in genetic networks
Nature Biotechnology (2018)
-
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
Frontiers of Medicine (2018)
-
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Nature Reviews Clinical Oncology (2017)